Disclosure of Clinical Study Information

Registration of Clinical Study Information and Disclosure of Clinical Study Results

Sumitomo Pharma Co., Ltd. believes that it should appropriately disclose information about and results of clinical studies (clinical trials) sponsored by Sumitomo Pharma, with the aim of providing greater transparency of such clinical study data and realizing the full value thereof for contributing to scientific advancement, promotion of innovation, and enhancement of public health. Based on this recognition, we consistently register information on clinical studies and appropriately disclose study results in compliance with relevant laws, regulatory requirements, and industry guidelines for each country.

Registration of Clinical Study Information and Publication of Summaries of Study Results

Sumitomo Pharma registers and discloses information about clinical studies that it sponsors, and the summarized results thereof, in the following clinical trial information registration databases, which are publicly accessible.

Publication of Clinical Study Results

Sumitomo Pharma seeks to have results from all phase 3 clinical studies and any clinical study results of significant medical importance on its sponsored studies presented and published, regardless of study or trial outcomes, at scientific meeting and in peer-reviewed journals.

Inquiries

Please contact us if you have any inquiries relating to disclosure of clinical study information. Please note that we may not be able to respond depending on the nature of the inquiry.